• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

FDA Releases Transfusion-Related Fatalities Report

May 10, 2013

The United States Food and Drug Administration (FDA) has published data on transfusion-related fatalities in FY2012, confirming that the blood supply today is safer than ever before. In FY2012, the FDA received 88 fatality reports, among which 74 were cases among transfusion recipients and 14 were post-donation cases. Further analysis found that among the 74 transfusion recipient cases, 38 (51%) were conclusively transfusion-related, 9 (12%) were unrelated to transfusion, and 27 (36%) were possibly transfusion-related. Consistent with trends in previous years, the most common complications among transfusion-related fatalities were transfusion related acute lung injury (TRALI) (45%), followed by hemolytic transfusion reactions (21%) and transfusion associated circulatory overload (TACO) (21%). Cases of TRALI and TACO increased slightly from FY2011.

Reference

1.    US Food and Drug Administration.  Center for Biologics Evaluation and Research.  Fatalities Reported to FDA Following  Blood Collection and Transfusion: Annual Summary for Fiscal Year 2012. 4/18/2013. Accessed 5/8/2013.

Filed Under

  • News
  • Policy and Guidelines
  • Quality Control and Regulatory

Recommended

  • Reduced Transfusion-Transmitted Hepatitis B and Hepatitis C Infections in Sub-Saharan Africa

  • National Survey Finds Stable Adverse Transfusion Reaction Rate in the U.S.

  • VIDEO: A Validated Transfusion Medicine Exam

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • RBCs with Reduced Deformability are Removed from Circulation

  • Array-based, comprehensive genotyping for erythroid, platelet, neutrophil and leukocyte antigens

  • Acute Normovolemic Hemodilution Does Not Reduce RBC Transfusions

  • Blood Donation Teams—a Novel Strategy to Support Novice Donors

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley